KINIKSA PHARMACEUTICALS INTE (KNSA) Stock Price, Quote, News and Overview
NASDAQ:KNSA - Nasdaq - GB00BRXB0C07 - Common Stock - Currency: USD
KNSA Quote, Performance and Key Statistics
29.02
+0.18 (+0.62%)
The current stock price of KNSA is 29.02 USD. In the past month the price increased by 3.9%. In the past year, price increased by 36.69%.
KNSA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.43 | 334.31B | ||
| AMGN | AMGEN INC | 14.2 | 158.50B | ||
| GILD | GILEAD SCIENCES INC | 13.98 | 134.62B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 118.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.24 | 58.58B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 41.79B | ||
| ARGX | ARGENX SE - ADR | 98.19 | 34.47B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.54 | 31.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.45B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.46B | ||
| INSM | INSMED INC | N/A | 19.46B | ||
| NTRA | NATERA INC | N/A | 18.97B |
Related stock screener links
About KNSA
Company Profile
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. Its portfolio of immune-modulating assets, ARCALYST, abiprubart and mavrilimumab, is based on strong biologic rationale or validated mechanisms, targets a spectrum of underserved cardiovascular and autoimmune conditions and offers the potential for differentiation. ARCALYST is an interleukin-1α and interleukin-1β cytokine trap. ARCALYST is used for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist.
Company Info
KINIKSA PHARMACEUTICALS INTE
23 Old Bond Street, Floor 3
London HM11 GB
CEO: Sanj K. Patel
Employees: 315
KINIKSA PHARMACEUTICALS INTE / KNSA FAQ
What is the stock price of KINIKSA PHARMACEUTICALS INTE today?
The current stock price of KNSA is 29.02 USD. The price increased by 0.62% in the last trading session.
What is the ticker symbol for KINIKSA PHARMACEUTICALS INTE stock?
The exchange symbol of KINIKSA PHARMACEUTICALS INTE is KNSA and it is listed on the Nasdaq exchange.
On which exchange is KNSA stock listed?
KNSA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KINIKSA PHARMACEUTICALS INTE stock?
12 analysts have analysed KNSA and the average price target is 39.37 USD. This implies a price increase of 35.67% is expected in the next year compared to the current price of 29.02. Check the KINIKSA PHARMACEUTICALS INTE stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KINIKSA PHARMACEUTICALS INTE worth?
KINIKSA PHARMACEUTICALS INTE (KNSA) has a market capitalization of 2.12B USD. This makes KNSA a Mid Cap stock.
How many employees does KINIKSA PHARMACEUTICALS INTE have?
KINIKSA PHARMACEUTICALS INTE (KNSA) currently has 315 employees.
What are the support and resistance levels for KINIKSA PHARMACEUTICALS INTE (KNSA) stock?
KINIKSA PHARMACEUTICALS INTE (KNSA) has a support level at 28.42 and a resistance level at 29.06. Check the full technical report for a detailed analysis of KNSA support and resistance levels.
Is KINIKSA PHARMACEUTICALS INTE (KNSA) expected to grow?
The Revenue of KINIKSA PHARMACEUTICALS INTE (KNSA) is expected to grow by 34.22% in the next year. Check the estimates tab for more information on the KNSA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy KINIKSA PHARMACEUTICALS INTE (KNSA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KNSA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KNSA, evaluating the profitability, health, valuation and growth aspects
- KINIKSA PHARMACEUTICALS INTE (KNSA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KINIKSA PHARMACEUTICALS INTE (KNSA) Sales and EPS estimates to see what analysts future expectations are.
- KINIKSA PHARMACEUTICALS INTE (KNSA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KINIKSA PHARMACEUTICALS INTE (KNSA) Insider and Institutional Ownership to learn about the owners and their transactions.
- KINIKSA PHARMACEUTICALS INTE (KNSA) Stock Chart to make your own analysis
- KINIKSA PHARMACEUTICALS INTE (KNSA) Latest news and press-releases to stay up to date.
Does KINIKSA PHARMACEUTICALS INTE (KNSA) stock pay dividends?
KNSA does not pay a dividend.
What is the Price/Earnings (PE) ratio of KINIKSA PHARMACEUTICALS INTE (KNSA)?
KINIKSA PHARMACEUTICALS INTE (KNSA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.25).
What is the Short Interest ratio of KINIKSA PHARMACEUTICALS INTE (KNSA) stock?
The outstanding short interest for KINIKSA PHARMACEUTICALS INTE (KNSA) is 5.08% of its float. Check the ownership tab for more information on the KNSA short interest.
KNSA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to KNSA. When comparing the yearly performance of all stocks, KNSA is one of the better performing stocks in the market, outperforming 88.91% of all stocks.
KNSA Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to KNSA. KNSA has an excellent financial health rating, but there are some minor concerns on its profitability.
KNSA Financial Highlights
Over the last trailing twelve months KNSA reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS decreased by -327.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.83% | ||
| ROE | -3.71% | ||
| Debt/Equity | 0 |
KNSA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to KNSA. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 221.23% and a revenue growth 34.22% for KNSA